Integrating Cytogenetics in Acute Myeloid Leukaemia (AML) Decision-Making: A Case Study

Dr Priyanka Mehta, Consultant Haematologist, and Dr Rachel Protheroe, Haematologist and Transplant Consultant, both from the University Hospitals Bristol discuss their approach in treating patients with AML and how cytogenetic testing has transformed this approach. While Consultant Clinical Scientist of the Bristol Genetics Laboratory, Dr Chris Wragg, gives an overview of the cytogenetic testing process in his lab and the changes he has implemented so results can be made available in a timely manner.

Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Cytogenetics

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2000174 | March 2021